Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has approved VaxRabeo (rabies virus inactivated strain Wistar) for pre‑exposure prophylaxis (PrEP) and post‑exposure prophylaxis (PEP) against rabies for all age groups — a dual‑setting approval supported by a comprehensive clinical program benchmarked against Sanofi’s existing standard‑of‑care rabies vaccines.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC) |
| Approval Type | Marketing approval – PrEP and PEP |
| Product | VaxRabeo (rabies virus inactivated strain Wistar) |
| Indication | Pre‑exposure prophylaxis and post‑exposure prophylaxis against rabies |
| Population | All age groups |
| Approval Date | 19 November 2026 |
| Comparators in Clinical Program | Sanofi’s current standard‑of‑care vaccines – Verorab and Imovax Rabies |
Vaccine Profile & Manufacturing Technology
- Strain & Platform: Rabies virus inactivated strain Wistar, manufactured using state‑of‑the‑art Vero‑cell technology.
- Formulation: Engineered to minimize the risk of allergic reactions, improving tolerability across diverse patient populations.
- Shelf Life: Longer shelf life than Sanofi’s current rabies vaccines.
- Thermostability: Improved thermostability — a critical advantage for storage and distribution, particularly in endemic regions with constrained cold‑chain infrastructure.
Clinical Evidence – Head‑to‑Head Program vs. Standard of Care
| Setting | Finding |
|---|---|
| PrEP (All Age Groups) | Comparable protective antibody levels versus Verorab and Imovax Rabies |
| PEP (All Age Groups) | Similar immunogenicity profile versus standard of care |
| Booster (12 or 24–36 Months Post‑PrEP) | High boostability of the booster dose |
| Safety | Profile in line with existing vaccines; no significant safety concerns |
The EU approval is supported by a comprehensive clinical program comparing VaxRabeo with Sanofi’s current standard‑of‑care vaccines (Verorab and Imovax Rabies) in both PrEP and PEP settings, across all age groups and WHO‑recommended schedules. VaxRabeo demonstrated comparable protective antibody levels in PrEP, a similar immunogenicity profile in PEP, and high boostability of the booster dose administered 12 or 24–36 months after PrEP, with a safety profile in line with existing vaccines and no significant safety concerns.
Market Impact & Outlook
- Rabies Burden: Rabies remains a fatal viral disease transmitted principally through dog bites, with the vast majority of deaths occurring in Asia and Africa — underscoring sustained global demand for both PrEP for at‑risk populations and PEP for exposure management.
- Portfolio Renewal: VaxRabeo positions Sanofi to modernize its established rabies franchise, building on the legacy of Verorab and Imovax Rabies with improved formulation and stability attributes.
- Logistics Advantage: Longer shelf life and improved thermostability reduce cold‑chain burden and wastage, potentially strengthening competitiveness in tenders and public immunization programs in endemic markets.
- Broad Label: Approval for all age groups in both PrEP and PEP maximizes prescriber flexibility and aligns with WHO‑recommended schedules for rabies prevention.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization, market uptake, distribution and potential global expansion of VaxRabeo. Actual results may differ materially due to risks inherent in commercial launch, procurement and tender dynamics, competitive developments and regulatory decisions in other jurisdictions.-Fineline Info & Tech
